MetLife Investment Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.53M | Buy |
7,761
+466
| +6% | +$152K | 0.01% | 883 |
|
|
2025
Q1 | $1.97M | Sell |
7,295
-9
| -0.1% | -$2.43K | 0.01% | 1044 |
|
|
2024
Q4 | $1.72M | Sell |
7,304
-14
| -0.2% | -$3.29K | 0.01% | 1122 |
|
|
2024
Q3 | $2.01M | Sell |
7,318
-144
| -2% | -$39.6K | 0.01% | 1016 |
|
|
2024
Q2 | $1.81M | Buy |
7,462
+856
| +13% | +$208K | 0.01% | 1017 |
|
|
2024
Q1 | $987K | Buy |
6,606
+102
| +2% | +$15.2K | 0.01% | 1308 |
|
|
2023
Q4 | $1.24M | Sell |
6,504
-92
| -1% | -$17.6K | 0.01% | 1185 |
|
|
2023
Q3 | $1.17M | Buy |
6,596
+4
| +0.1% | +$708 | 0.01% | 1155 |
|
|
2023
Q2 | $1.25M | Sell |
6,592
-858
| -12% | -$163K | 0.01% | 1142 |
|
|
2023
Q1 | $1.49M | Buy |
7,450
+18
| +0.2% | +$3.61K | 0.01% | 1023 |
|
|
2022
Q4 | $1.77M | Sell |
7,432
-58
| -0.8% | -$13.8K | 0.01% | 955 |
|
|
2022
Q3 | $1.5M | Buy |
7,490
+5
| +0.1% | +$1K | 0.01% | 1000 |
|
|
2022
Q2 | $1.09M | Sell |
7,485
-278
| -4% | -$40.5K | 0.01% | 1166 |
|
|
2022
Q1 | $1.27M | Buy |
+7,763
| New | +$1.27M | 0.01% | 1191 |
|
|
2019
Q2 | – | Sell |
-129
| Closed | -$12.1K | – | 2432 |
|
|
2019
Q1 | $12.1K | Buy |
129
+7
| +6% | +$654 | ﹤0.01% | 2375 |
|
|
2018
Q4 | $8.9K | Sell |
122
-1
| -0.8% | -$73 | ﹤0.01% | 2389 |
|
|
2018
Q3 | $10.8K | Buy |
+123
| New | +$10.8K | ﹤0.01% | 2431 |
|